The SIU 2017 Spring Term educational programme aims to guide participants through many of the key practical skills required to take an idea from laboratory research and published work to a fully formed and translatable business idea. The talks will cover subjects such as; combining roles in academia and biotech; analysing, fine tuning and executing your plan for a biotech business; patenting your research to add value and defensibility to your business; and insights into how to attract the big science funders.


GUEST SPEAKER: Cecily Morrison

Mong Hall, Sidney Sussex College (Sidney Street) - (7pm to 9pm)






This event will be looking at how the relatively recent technology boom is affecting and changing the age old practice of medicine. This follows the the shift in healthcare to prioritising quality of life intended to support treatments, rather than treatments alone. We will be discussing how to begin to approach the biggest problems using technology tools. Looking into which challenges to target first, as well as the development of such projects. Furthermore, how will this fast paced field change in the coming years? Join us for an exciting event which looks into the changing landscape of healthcare.


Dramatic social change and a shifting economic market lead us into a world which prioritises different values and holds new types of attitudes. So how will science shift to adapt to this altered landscape? This talk will look at the role, purpose, and potential of science - addressing how the community approaches inclusivity. The public perception and understanding of science is valuable not only in terms of improving services such as health care, but also in distribution of funding, and economic return - each of which can be strongly dictated by society.


location to be confirmed soon! - (7PM TO 9PM)




location to be announced soon! - (7PM TO 9PM)








We're always innovating - so many people working on so many projects in different ways in different places. It's an exciting explosion of creativity driving us forward - but how does this translate to education? New discoveries and breakthroughs in technology and science should be fed back into different levels of education. How have we done it before, and should we change it now? What's the difference between a promising new field, and a fad? What kind of materials should be focused on that will best prepare the next generation for their unique challenges and opportunities? Join us in discussing this highly fascinating area which has the potential to radically change the future.

Guest Speakers: Simon Lambden, Su Metcalfe, Attila Csordas, Portia Asli 

Department of engineering, university of Cambridge (7-9 pm)

Dr Simon Lambden is part of the academic intensive care team of the University. He will present his experience in launching and securing funding for his new start-up based on a new treatment for sepsis, a life threatening condition that arises when the body’s response to infection causes injury to its own tissues. He will address the issue of convincing private sector funders to invest in a novel idea.

Su Metcalfe is the founder and CSO of LifNano Therapeutics. LIFNanoRx is a nano-bio-med company focused on treatment of Multiple Sclerosis (MS), an auto-immune inflammatory disease of the central nervous system. Using a critical stem cell factor with unique biological properties alongside nanoparticle technology, they present a new approach to the treatment of MS.

Attila Csordas is the founder AgeCurve, a startup with a vision to provide deep molecular age profiles for every grown-up. They believe that the complexity of ageing can be captured reliably by detecting molecular patterns and analysing big chunks of people’s proteome from saliva, to learn and to assess lifestyle interventions.

Portia Asli is the chief commercial officer of Vocalens, a Cambridge University spin-out startup co-founded by Cambridge engineers and MBAs, developing smart wearable assistive technology for people with visual impairment.

Session 4: Meet the Founder: Pitch Perfect

Come listen to pitch-structured presentations by successful biomedical start-ups based in Cambridge. These companies are excited to share how they managed to launch a business from a scientific idea and will discuss their background, current project and future directions.

guest speakers: ben bleasdale, peter hiscocks, tamzin byrne

University of Cambridge Judge Business School (7-9 pm)

Ben Bleasdale is currently a Senior Policy officer at Wellcome Trust. He obtained his PhD in Virology at Imperial College London, before finding himself in the position of Policy Officer at the Academy of Medical Sciences.

Peter Hiscocks is the CEO of Cambridge Judge Business School Executive Education, as well as a lecturer in entrepreneurship and innovation management. He was also the Director of Cambridge Enterprise as well as the first Director of the Cambridge Entrepreneurship Centre. In the past he spent a number of years in the private sector working in product development in large companies before starting his own businesses, a few of which have been very successful and sold. He is also the Chairman of a £20 million seed-fund that helps fund new business start-ups and is on the advisory boards of a large venture capital company.

Tamzin Byrne is the Programme Coordinator of Cambridge Social Ventures. With a background in journalism and science communication, she has written about everything from the God particle to stem cells for universities, government agencies, international research centres and start-ups.

session 5: The not so basic side of basic science

Nowadays, considerable resources are invested into basic science but the question arises of whether it efficiently leads to the development of new therapies and can justify its cost in comparison to clinical, translational research. Following a recession, Brexit, Donald Trump and a snap general election, the government and how it behaves has never been under such scrutiny by the general public. As such, funding the endeavours of an ivory tower scientist becomes less and less of a priority, whilst the need for life saving treatments is only increasing. What is the route of the next big discovery? Will academia, with its track record of sparking world changing discoveries lead to the development of new drugs, therapies and devices, or will clinical, translational research take the crown (and the funding)? Join us on June 13th at the Judge Business school, University of Cambridge, for what promises to be a lively discussion between four different fields each invested in this question.